Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

MiniMed 780G System Gains CE Mark for Abbott Instinct Sensor

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

ShiftMed Highlights Open Shift Management Cost...

ShiftMed has released its 2026 Open Shift Management Report,...

Jaime Caballero, MD, on The Efficiency...

In the high-stakes world of surgery, time is more...

FedEx KMDIA Partnership Boosts Korean Medical...

Federal Express Corporation (FedEx) has entered into a collaboration...

MiniMed Group, a global provider of integrated insulin delivery technologies, has secured CE (Conformité Européenne) Mark approval to use the MiniMed 780G system with the Instinct sensor developed by Abbott. The authorisation broadens the number of compatible sensors available for the company’s automated insulin delivery platform, expanding options for users of the system.

“At MiniMed, every advancement begins with listening to the needs of people living with diabetes,” said Que Dallara, CEO of MiniMed. “By offering more sensor flexibility within a fully integrated system backed by the proven clinical outcomes of our MiniMed™ 780G system1,2,3,4 we’re helping lighten the burden of daily management and giving individuals the freedom to choose what works best for them.”

The MiniMed 780G system already supports the Guardian™ 4 and Simplera Sync™ sensors, each designed to provide up to seven days of wear time. Following the latest approval, the system will also operate with the Instinct sensor, which has been developed exclusively by Abbott for MiniMed’s automated insulin delivery (AID) system. The Instinct sensor is described as the world’s smallest, thinnest and most discreet continuous glucose monitoring (CGM) sensor and can be worn for up to 15 days.

With the addition of the Instinct sensor, individuals using the MiniMed™ 780G system can now select between sensors offering either 7-day or 15-day wear durations, enabling greater flexibility depending on personal preference and lifestyle requirements. MiniMed plans to introduce the MiniMed™ 780G system with the Instinct sensor commercially in the first European countries during the summer of 2026. The company also intends to showcase the complete system at the 19th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2026) scheduled to take place in Barcelona from March 11–14, 2026. In Europe, the MiniMed™ 780G system is indicated for individuals aged two years and older with insulin-requiring diabetes (type 1 and type 2) whose total daily insulin dose is six units or more, and the system is also CE marked for use during pregnancy.

MEDICAL FAIR ASIA 2026

Latest stories

Related stories

ShiftMed Highlights Open Shift Management Cost Gap in US

ShiftMed has released its 2026 Open Shift Management Report,...

FedEx KMDIA Partnership Boosts Korean Medical Exports Growth

Federal Express Corporation (FedEx) has entered into a collaboration...

MHRA Advances AI Airlock with £3.6 Mn Multi-Year Funding

The Medicines and Healthcare products Regulatory Agency (MHRA) has...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »